How a specific immune cell helps calm allergic lung inflammation
Immunoregulatory Role of Conventional Dendritic Cell Type 2 in Allergic Lung Inflammation
This project looks at how a type of immune cell called CX3CR1+ cDC2 may reduce inflammation in allergic asthma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11332457 on NIH RePORTER |
What this research studies
Researchers will study a subset of immune cells (CX3CR1+ cDC2) that appear to act differently from other dendritic cells in the lungs. They will compare gene activity in these cells from mouse and human lung samples and use laboratory models to see how the cells change allergic inflammation. The team will test how these cells signal to other immune cells and whether boosting their activity helps the lung recover. Results may point to new ways to encourage natural anti-inflammatory responses in asthma.
Who could benefit from this research
Good fit: People with allergic asthma or other allergic lung inflammation who can provide samples or participate in related clinic visits would be the most relevant candidates to help this research.
Not a fit: People without allergic asthma (for example, those with non-allergic lung conditions) or those seeking an immediate treatment change are unlikely to benefit directly from this basic research.
Why it matters
Potential benefit: If successful, this work could point to new treatments that reduce asthma-related airway inflammation by enhancing naturally protective immune cells.
How similar studies have performed: Prior work, including the investigators' own studies, supports an anti-inflammatory role for CX3CR1-expressing myeloid cells and lung macrophages, but applying this specifically to CX3CR1+ cDC2 in asthma is a newer area of study.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Park, Gye Young — University of Illinois at Chicago
- Study coordinator: Park, Gye Young
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.